BC Innovations | Oct 3, 2019
Emerging Company Profile

X-Vax: Bucking dogma in HSV vaccine development

Veering from the field’s focus on neutralizing antibodies, X-Vax is developing vaccines that elicit non-neutralizing antibodies that direct the immune system to kill infected cells. Its lead candidate is in preclinical development to prevent HSV...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BC Extra | Jun 25, 2016
Company News

CHMP recommendations include Keytruda for NSCLC

EMA's CHMP recommended approval of PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) for non-small cell lung cancer, as well as asthma treatment Cinqaero reslizumab from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and cell...
BC Innovations | Jun 9, 2016
Tools & Techniques

Entrez LA Cell

LA Cell Inc. is developing a new way of reaching the long sought-after goal of getting antibodies inside cells by chemically modifying the molecules. While the company believes it can expand the druggable universe of...
BC Week In Review | Mar 31, 2014
Clinical News

TK regulatory update

MolMed said EMA accepted for review an MAA seeking conditional approval of TK as adjunctive treatment for high-risk leukemia patients undergoing hematopoietic stem cell transplantation (HSCT). MolMed said TK - which comprises donor lymphocytes engineered to...
BC Week In Review | Mar 10, 2014
Clinical News

TK regulatory update

MolMed submitted an MAA to EMA seeking conditional approval of TK as adjunctive treatment for high-risk leukemia patients undergoing hematopoietic stem cell transplantation (HSCT). MolMed said TK - which comprises donor lymphocytes engineered to express the...
BioCentury | Mar 10, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Endo International plc (NASDAQ:ENDP; TSX:ENL) was off $6.06 to $73.76 last week after FDA approved a resubmitted NDA for Aveed testosterone to treat male hypogonadism. The company said it plans to launch the...
BC Extra | Mar 8, 2014
Company News

MolMed seeking conditional EU approval of TK

MolMed S.p.A. (Milan:MLM) submitted an MAA to EMA seeking conditional approval of TK as adjunctive treatment for high-risk leukemia patients undergoing hematopoietic stem cell transplantation (HSCT). MolMed said TK -- which comprises donor lymphocytes engineered...
BC Week In Review | Nov 11, 2013
Clinical News

HerpV: Phase II data

Top-line data from the double-blind, U.S. Phase II C-400-02 trial in 80 HSV-2-positive patients with a history of 1-9 herpes recurrences within the prior 12 months showed that 3 injections of 240 µg HerpV given...
BC Week In Review | Mar 11, 2013
Clinical News

HerpV with QS-21: Completed Phase IIa enrollment

Agenus completed enrollment of >=75 HSV-2-positive patients with a history of frequent disease recurrence in the double-blind, placebo-controlled, U.S. Phase IIa C-400-02 trial evaluating HerpV plus Agenus' QS-21 Stimulon adjuvant. Patients will receive a booster...
Items per page:
1 - 10 of 15